Modality
Multispecific
MOA
SGLT2i
Target
Cl18.2
Pathway
Checkpoint
ADHDRBAngelman
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
~Apr 2024
→ ~Jul 2025
Phase 2
Oct 2025
→ Aug 2026
Phase 2Current
NCT05948537
1,535 pts·RB
2025-10→2026-08·Completed
1,535 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-134mo awayPh3 Readout· RB
Trial Timeline
Q42026Q2Q3
P2/3
Complet…
Catalysts
Ph3 Readout
2026-08-13 · 4mo away
RB
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05948537 | Phase 2/3 | RB | Completed | 1535 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| MRN-8225 | Moderna | Preclinical | TNFα |